Pulmonary function and airway responsiveness in mild to moderate asthmatics given repeated inhaled doses of zanamivir

Respiratory Medicine

Volumn 94, Issue 2, 2000, Pages 166-173

  Cass, L M R ^a   Gunawardena, K A ^b   Macmahon, M M ^b   Bye, A ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Chiltern International Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; METHACHOLINE; PLACEBO; SALBUTAMOL; THEOPHYLLINE; ZANAMIVIR;

ADULT; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; INFLUENZA; LIVER DYSFUNCTION; LUNG COMPLICATION; LUNG FUNCTION; MALAISE; MALE; NAUSEA; PATIENT COMPLIANCE; PEAK EXPIRATORY FLOW; POWDER INHALER; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; SORE THROAT; THORAX PAIN; VERTIGO; VOMITING; WHEEZING;

EID: 0034141234     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1053/rmed.1999.0718     Document Type: Article

References (17)

1. Von Itzstein M., Wu W Y, Kok G B. Rational design of potent sialidase based inhibitors of influenza virus replication. Nature. 363:1993;418-423.
2. Woods J M, Bethell R C, Coates J AV. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialadase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother. 37:1993;1473-1479.
3. Ryan D., Ticehurst J., Dempsey M., Penn C R. Inhibition of influenza virus replication in mice by GG167 is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob Agents Chemother. 38:1994;2270-2275.
4. Ryan D., Ticehurst J., Dempsey M H. GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-n-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets. Antimicrob Agents Chemother. 39:1995;2583-2584.
5. Dines G D, Bethell R., Daniel M. Preclinical development of low toxicity drugs; Focus on zanamivir, an anti-influenza drug. Drug Safety. 19:1998;233-241.
6. Hayden F G, Treanor J J, Betts R F, Lobo M., Esinhart J D, Hussey E K. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA. 275:1996;295-299.
7. Walker J B, Hussey E K, Treanor J J. Effects of neuraminidase inhibitor zanamivir on otologic manifestations of experimental human influenza. J Infect Dis. 176:1997;1417-1422.
8. Hayden F G, Osterhaus A DME, Treanor J J. Efficacy and Safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. New Eng J Med. 337:1997;874-880.
9. Matsumoto, K, Nerome, K, Numasaki, Y, et al., Inhaled and intranasal GG167 in the treatment of influenza A and B; preliminary results, 1996, 1123, 713, 717.
10. Lancet. 352:1998;1877-1881.
11. Monto A S, Fleming D M, Henry D. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis. 180:1999;254-261.
12. Cass, L, MR, Efhymiopoulos, C, Bye, A, Review of the pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal dosing in healthy volunteers, Clinical Pharmacokinetics, 1999, 36, 1, 11.
13. Nicholson K G, Kent J., Ireland D C. Respiratory viruses and exacerbations of asthma in adults. B. Med. J. 307:1993;982-986.
14. Teichtahl H., Buckmaster N., Pertnikovs E. The incidence of respiratory tract infection in adults requiring hospitalisation for asthma. Chest. 112:1997;591-596.
15. Quanjer P hH, Dalhuijsen A., Van Zomerren B C. Summary equations of reference values. Bull Europ Physiopathol Respir. 19:1983;45-51.
16. Qunajer P hH, Tammelling G J, Cotes J E, Pedersen O F, Peslin R., Yernault J-C. Lung volumes and forced ventilatory flows: Report working party, standardization of lung function tests, European Community of Steel and Coal: Official Statement of the Eurpean Respiratory Society. Eur Respir J. 6:1993;5-40.
17. Sterk P J, Fabbri L M, Quanjer Ph H. Airway Responsiveness: Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Eur Respir J. 6:1993;53-83.